A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.

doi:10.1021/acs.jmedchem.0c00382

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.

Journal of medicinal chemistry - 11 Feb 2021

Haugaard-Kedström Linda M, Clemmensen Louise S, Sereikaite Vita, Jin Zeyu, Fernandes Eduardo F A, Wind Bianca, Abalde-Gil Flor, Daberger Jan, Vistrup-Parry Maria, Aguilar-Morante Diana, Leblanc Raphael, Egea-Jimenez Antonio L, Albrigtsen Marte, Jensen Kamilla E, Jensen Thomas M T, Ivarsson Ylva, Vincentelli Renaud, Hamerlik Petra, Andersen Jeanette Hammer, Zimmermann Pascale, Lee Weontae, Strømgaard Kristian

Abstract excerpt

Despite the recent advances in cancer therapeutics, highly aggressive cancer forms, such as glioblastoma (GBM), still have very low survival rates. The intracellular scaffold protein syntenin, comprising two postsynaptic density protein-95/discs-large/zona occludens-1 (PDZ) domains, has emerged as a novel therapeutic target in highly malignant phenotypes including GBM. Here, we report the development of a novel,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Glioblastoma

Share to High-Throughput Screening Assays

Share to Ligands

Share to Microsomes

Share to X-Ray Diffraction

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 33502198
DOI: 10.1021/acs.jmedchem.0c00382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.PMID 33502198Read ↗

Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/SynteninSemantic proximity Read ↗

Advances Toward Lsd1 Inhibitors for Cancer TherapySemantic proximity Read ↗

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of GlioblastomaSemantic proximity Read ↗

The serine-threonine kinase TAO3 promotes cancer invasion and tumor growth by facilitating trafficking of endosomes containing the invadopodia scaffold TKS5αSemantic proximity Read ↗

Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applicationsSemantic proximity Read ↗

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaSemantic proximity Read ↗

Neuroblastoma and its Target Therapies: A Medicinal Chemistry ReviewSemantic proximity Read ↗

Targeting BACH1 by HPPE inhibits the Wnt/β-catenin pathway and malignant phenotype in glioblastoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.